论文部分内容阅读
迄今为止,对进行期胃癌的浆膜浸润与腹膜转移尚无理想的治疗方法,且其发生率甚高,文献统计约为36.8～69％,被公认是癌复发和治疗失败的主要原因之一;由于肉眼很难观察到这类微癌灶在腹膜的存在,无法用手术完全切除,全身化疗亦难发挥疗效,故其预后极坏。而本世纪八十年代初才试用于临床的腹腔内温热灌流(Iintraperitoneal hyperthermic perfusion,IPHP)化疗,不仅能将种植于腹膜和浮游于腹水中的癌细胞杀死,而且还可把漂浮的癌细胞冲洗出来,是目前较实用、简便的癌治疗新技术。鉴于国内缺乏系统研究报道,所以本文简要对国外有关IPHP化疗对进行期胃癌治疗的临床应用及其进展作一概述。
So far, there is no ideal treatment for the serosal infiltration and peritoneal metastasis of gastric cancer, and its incidence is very high, the literature statistics is about 36.8 to 69%, and it is recognized as one of the main reasons for cancer recurrence and treatment failure. Because it is difficult for the naked eye to observe the presence of this type of microcancer in the peritoneum, it cannot be completely removed by surgery, and systemic chemotherapy is also difficult to exert its efficacy, so its prognosis is extremely poor. However, in the early 1980s, it was tried clinically for intraperitoneal hyperthermic perfusion (IPHP) chemotherapy. It can not only kill cancer cells that grow in the peritoneum and float in the ascites but also can cause floating cancer. Rinse out the cells is a new practical and simple cancer treatment technology. In view of the lack of systematic research reports in China, this article briefly outlines the clinical application and progress of overseas IPHP chemotherapy for advanced gastric cancer treatment.